

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁵: C07K 7/00, 7/08, 7/64, 15/08, 15/28, C12N 15/03, 15/04, 15/05, 15/06, 15/12, A61K 37/02	A1	(11) International Publication Number: WO 95/03325 (43) International Publication Date: 2 February 1995 (02.02.95)												
(21) International Application Number: PCT/US94/08305 (22) International Filing Date: 20 July 1994 (20.07.94) (30) Priority Data: <table border="0" style="width: 100%;"><tr><td style="width: 30%;">08/093,926</td><td style="width: 40%;">20 July 1993 (20.07.93)</td><td style="width: 30%;">US</td></tr><tr><td>08/095,769</td><td>26 July 1993 (26.07.93)</td><td>US</td></tr><tr><td>08/182,483</td><td>13 January 1994 (13.01.94)</td><td>US</td></tr><tr><td>08/243,879</td><td>17 May 1994 (17.05.94)</td><td>US</td></tr></table> (71) Applicant: UNIVERSITY OF CALIFORNIA, LOS ANGELES [US/US]; 1400 Ueberroth Building, 450 Hilgard Avenue, Los Angeles, CA 90024-1406 (US). (72) Inventors: LEHRER, Robert, L.; 2730 Washington Avenue, Santa Monica, CA 94043 (US). HARWIG, Sylvia, S., L.; 21911 Woodland Crest Drive, Woodland Hills, CA 91364 (US). KOKRYAKOV, Vladimir, N.; Apartment 3D, 435 S. Curson Avenue, Los Angeles, CA 90036 (US). (74) Agents: MURASHIGE, Kate, H. et al.; Morrison & Foerster, 2000 Pennsylvania Avenue, N.W., Washington, DC 20006 (US).		08/093,926	20 July 1993 (20.07.93)	US	08/095,769	26 July 1993 (26.07.93)	US	08/182,483	13 January 1994 (13.01.94)	US	08/243,879	17 May 1994 (17.05.94)	US	(81) Designated States: AU, BB, BG, BR, BY, CA, CH, CN, CZ, FI, HU, JP, KP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
08/093,926	20 July 1993 (20.07.93)	US												
08/095,769	26 July 1993 (26.07.93)	US												
08/182,483	13 January 1994 (13.01.94)	US												
08/243,879	17 May 1994 (17.05.94)	US												
(54) Title: PROTEGRINS (57) Abstract <p>Peptide-based compounds containing four invariant cysteine residues which have been optionally oxidized to contain two intramolecular disulfide bonds, or modified forms where the cysteines are replaced, are useful as preservatives and in preventing, treating or ameliorating viral or microbial infection in animals and plants, and in inactivating endotoxin. Exemplary peptides include the following in purified and isolated form: RGGRLCYCRRRFCVVCVGR, RGGRLCYCRRRFCICV, RGGGLCYCRRRFCVVCVGR, and RGGRLCYCRGWICFCVGR.</p>														

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

PROTEGRINS

This invention was made with funding from NIH Grant No. A122839. The U.S. Government has certain rights in this invention.

5. Technical Field

The invention relates to the field of antibiotic peptides. In particular, the invention concerns short peptides, some of which are isolated from porcine leukocytes, that have a wide range of antimicrobial activities.

Background Art

One of the defense mechanisms against infection by both animals and plants is the production of peptides that have antimicrobial and antiviral activity. Various classes of these peptides have been isolated from tissues both of plants and animals. One well known class of such peptides is the tachyplesins which were first isolated from the hemocytes of the horseshoe crab as described by Nakamura, T. et al. J Biol Chem (1988) 263:16709-16713. This article described the initial tachyplesin isolated, Tachyplesin I, from the Japanese species. Tachyplesin I is a 17-amino acid amidated peptide containing four cysteine residues providing two intramolecular cystine bonds. In a later article by this group, Miyata, T. et al. J Biochem (1989) 106:663-668, extends the studies to the American horseshoe crab and isolated a second tachyplesin, Tachyplesin II, consisting of 17 residues amidated at the C-terminus, also containing four cysteine residues and two intramolecular disulfide bonds. Two additional 18-mers, called polyphemusins, highly homologous to Tachyplesin II and containing the same positions for the four cysteine residues, were also isolated. Polyphemusin I and Polyphemusin II differ from each other only in the replacement of one arginine residue by a lysine. All of the peptides were described as having antifungal and antibacterial activity. A later

article by Murakami, T. et al. Chemotherapy (1991) 37:327-334, describes the antiviral activity of the tachyplesins with respect to vesicular stomatus virus; Herpes Simplex Virus I & II, Adenovirus I, Reovirus II and Poliovirus I were resistant to inactivation by Tachyplesin I. Morimoto, M. et al. Chemotherapy (1991) 37:206-211, found that Tachyplesin I was inhibitory to Human Immunodeficiency Virus. This anti-HIV activity was found also to be possessed by a synthetic analog of Polyphemusin II as described by Nakashima, H. et al. Antimicrobial Agents and Chemotherapy (1992) 1249-1255. Antiviral peptides have also been found in rabbit leukocytes as reported by Lehrer, R.I. et al. J Virol (1985) 54:467-472.

Other important classes of cysteine-containing antimicrobial peptides include the defensins, β -defensins and insect defensins. The defensins are somewhat longer peptides characterized by six invariant cysteines and three intramolecular cystine disulfide bonds. Defensins were described by Lehrer, R.I. et al. Cell (1991) 64:229-230; Lehrer, R.I. et al. Ann Rev Immunol (1993) 11:105-128. A review of mammalian-derived defensins by Lehrer, R.I. et al. is found in Annual Review Immunol (1993) 11:105-128; three patents have issued on the defensins: U.S. 4,705,777; U.S. 4,659,692; and U.S. 4,543,252. Defensins have been found in the polymorphonucleated neutrophils (PMN) of humans and of several other animals, as well as in rabbit pulmonary alveolar macrophages, and in murine small intestinal epithelial (Paneth) cells and in corresponding cells in humans.

β -Defensins are found in bovine respiratory epithelial cells, bovine granulocytes and avian leukocytes. See Selsted, M.E. et al. J Biol Chem (1993) 268:6641-6648 and Diamond, G. et al. Proc Natl Acad Sci (USA) (1991) 88:3952-3958. Insect defensins have been reported by Lambert, J. et al. Proc Natl Acad Sci (USA) (1989) 86:262-265.

Antifungal and antibacterial peptides and proteins have also been found in plants (Broekaert, W.F. et al. Biochemistry (1992) 31:4308-4314) as reviewed by Cornelissen, B.J.C. et al. Plant Physiol (1993) 101:709-712. Expression systems for the production of such peptides have been used to transform plants to protect the plants against such infection as described, for example, by Haln, R. et al. Nature (1993) 361:153-156.

The present invention provides a new class of antimicrobial and antiviral peptides, designated "protegrins" herein, representative members of which have been isolated from porcine leukocytes. These peptides are useful as antibacterial antiviral and antifungal agents in both plants and animals.

The isolation of the protegrin peptides of the invention was reported by the present applicants in a paper by Kokryakov, V.N. et al. FEBS (1993) 337:231-236 (July issue). A later publication of this group described the presence of a new protegrin, whose sequence, and that of its precursor, was deduced from its isolated cDNA clone. Zhao, C et al, FEBS Letters (1994) 346:285-288. An additional paper disclosing cationic peptides from porcine neutrophils was published by Mirgorodskaya, O.A. et al. FEBS (1993) 330:339-342 (September issue). Storici, P. et al. Biochem Biophys Res Comm (1993) 196:1363-1367, report the recovery of a DNA sequence which encodes a pig leukocyte antimicrobial peptide with a cathelin-like prosequence. The peptide is reported to be one of the protegrins disclosed hereinbelow.

The protegrins of the invention have also been found to bind to endotoxins -- i.e., the lipopolysaccharide (LPS) compositions derived from gram-negative bacteria which are believed responsible for gram-negative sepsis. This type of sepsis is an extremely common condition and is often fatal. Others have attempted to design and study proteins which bind LPS/endotoxin, and

illustrative reports of these attempts appear in Rustici, A. et al. Science (1993) 259:361-364; Matsuzaki, K. et al. Biochemistry (1993) 32:11704-11710; Hoess, A. et al. EMBO J (1993) 12:3351-3356; and Elsbach, P. et al.

5 Current Opinion in Immunology (1993) 5:103-107. The protegrins of the present invention provide additional compounds which are capable of inactivating of LPS and ameliorating its effects.

10 In addition to the foregoing, the protegrins of the invention are effective in inhibiting the growth of organisms that are associated with sexually transmitted diseases. It is estimated that 14 million people world-wide are infected with HIV and that millions of women sustain pelvic inflammatory disease each year. *Chlamydia*
15 *trachomatis* and *Neisseria gonorrhoeae* cause over half of this inflammatory disease although *E. coli*, *Mycoplasma hominis* and other infectious microorganisms can also be responsible. Pathogens include viral, bacterial, fungal and protozoan pathogens. It is especially important that
20 the antibiotics used to combat these infections be effective under physiological conditions. The protegrins of the present invention offer these properties.

Disclosure of the Invention

25 In one embodiment, the invention is directed to peptides of 16-18 amino acid residues characterized by four invariant cysteines and either by a characteristic pattern of basic and hydrophobic amino acids and/or being isolatable from animal leukocytes using the method of the invention. In a second embodiment, the invention is
30 directed to the above peptides wherein 1-4 of these cysteines is replaced by a hydrophobic or small amino acid. These peptides can be produced synthetically and some can be produced recombinantly or can be isolated from their native sources and purified for use as
35 preservatives or in pharmaceutical compositions in treating or preventing infection in animals.

Alternatively, the peptides can be formulated into compositions which can be applied to plants to protect them against viral or microbial infection. In still another approach, the DNA encoding the peptides can be expressed *in situ*, in animals or preferably in plants, to combat infections. The peptides are also useful as standards in antimicrobial assays and in binding endotoxins

Accordingly, in one aspect, the invention is directed to peptides of the formula:

$A_1-A_2-A_3-A_4-A_5-C_6-A_7-C_8-A_9-A_{10}-A_{11}-A_{12}-C_{13}-A_{14}-C_{15}-A_{16}-(A_{17}-A_{18})$ (1);

and the N-terminal acylated and/or

C-terminal amidated or esterified forms thereof, which is either in the optionally -SH stabilized linear or in a cystine-bridged form

wherein each of A_1 and A_9 is independently a basic amino acid;

each of A_2 and A_3 is independently a small amino acid;

each of A_5 , A_7 , A_{12} , A_{14} and A_{16} is independently a hydrophobic amino acid;

each of A_4 and A_{10} is independently a basic or a small amino acid;

A_{11} is a basic or a hydrophobic amino acid;

A_{17} is not present or, if present, is a small amino acid;

A_{18} is not present or, if present, is a basic amino acid, or a

modified form of formula (1) and the N-terminal acylated and/or C-terminal amidated or esterified forms thereof wherein each of 1-4 cysteines is independently replaced by a hydrophobic amino acid or a small amino acid;

with the proviso that if said compound is of the formula

RGGRLCYCRRRFCVCVGR,
RGGRLCYCRRRFCICV,

RGGGLCYCRRRFCVCVGR, or
RGGRLCYCRGWICFCVGR

in the amidated and di-cystine-bridged form, said compound is purified and isolated.

5 In another aspect, the invention comprises a purified and isolated peptide of the formula:

$A_1-A_2-A_3-A_4-A_5-C_6-A_7-C_8-A_9-A_{10}-A_{11}-A_{12}-C_{13}-A_{14}-C_{15}-A_{16}-(A_{17}-A_{18})(1a);$

and the amidated or esterified and/or
10 N-terminal acylated forms thereof, including the optionally SH-stabilized linear and the cyclic forms thereof

wherein A_{1-5} , A_7 , A_{9-12} and A_{14} and A_{16} , and, if present, A_{17} and A_{18} (i.e. A_n), represent amino acid residues

15 which peptides are isolatable from animal leukocytes by the methods similar to those described herein.

The invention is also directed to precursors of the peptides described above extended at the
20 N-termini and to recombinant materials encoding said precursors.

In still other aspects, the invention is directed to recombinant materials useful for the production of the peptides of the invention as well as
25 plants or animals modified to contain expression systems for the production of these peptides. The invention is also directed to pharmaceutical compositions and compositions for application to plants containing the peptides of the invention as
30 active ingredients or compositions which contain expression systems for production of the peptides or for *in situ* expression of the nucleotide sequence encoding these peptides. The invention is also directed to methods to prepare the invention peptides
35 synthetically, to antibodies specific for these peptides, and to the use of the peptides as preservatives.

In other aspects, the invention is directed to the use of the compounds of the invention as standards in antimicrobial assays. The compounds may also be used as antimicrobials in solutions useful in eye care, such as contact lens solutions, and in topical or other pharmaceutical compositions for treatment of sexually transmitted diseases (STDs). The invention is also directed to use of the invention compounds as preservatives for foods or other perishables. As the invention peptides can inactivate endotoxin, the invention is also directed to a method to inactivate endotoxins using the compounds of the invention and to treat gram-negative sepsis by taking advantage of this property.

Brief Description of the Drawings

Figure 1 shows the elution pattern of a concentrate of the ultrafiltrate of porcine leukocytes applied to a Biogel P10 column.

Figure 2 shows the antibacterial activity of the P10 fractions obtained from elution of the column described in Figure 1.

Figure 3 shows an elution pattern obtained when fractions 76-78 from the Biogel P10 column of Figure 1 is applied to HPLC.

Figure 4 shows the antimicrobial activity of the purified porcine protegrins of the invention:

Figure 4a shows antibacterial activity against *E. Coli*;

Figure 4b shows antibacterial activity against *Listeria monocytogenes*;

Figure 4c shows antifungal activity against *Candida albicans*;

Figure 4d shows antibacterial activity against *S. aureus*.

Figure 4e shows antibacterial activity against *K. pneumoneae*.

Figure 5 shows the effect of various test conditions on antimicrobial activity:

Figure 5a shows activity against *Candida albicans* in 100 μ M NaCl;

Figure 5b shows activity against *E. Coli* in 100 μ M NaCl;

Figure 5c shows activity against *Candida albicans* in 90% fetal calf serum.

Figure 6 shows the antimicrobial activity of the linear forms of the protegrins under various test conditions:

Figure 6a shows the activity against *E. coli* in 10 mM phosphate-citrate buffer, pH 6.5;

Figure 6b shows the activity against *E. coli* in the same buffer with 100 mM NaCl;

Figure 6c shows the activity against *L. monocytogenes* in the buffer of Figures 6a-6b;

Figure 6d shows the activity against *L. monocytogenes* in the same buffer with the addition of 100 mM NaCl;

Figure 6e shows the activity against *C. albicans* in the presence of 10 mM phosphate; and

Figure 6f shows the activity against *C. albicans* in the presence of 10 mM phosphate plus 100 mM NaCl.

Figure 7 shows a composite of cDNA encoding the precursors of PG-1, PG-2, PG-3 and PG-4.

Figure 8 shows the amino acid sequences of the protegrins of Figure 7.

Figures 9a-9d show the effects of various protegrins against various target microbes.

Modes of Carrying Out the Invention

The peptides of the invention are described by the formula:

$A_1-A_2-A_3-A_4-A_5-C_6-A_7-C_8-A_9-A_{10}-A_{11}-A_{12}-C_{13}-A_{14}-C_{15}-A_{16}-(A_{17}-A_{18})$, (1)

and its defined modified forms. Those peptides which occur in nature must be in purified and isolated form.

The designation A_n in each case represents an amino acid at the specified position in the peptide. As A_{17} and A_{18} may or may not be present, the peptides of the invention contain either 16, 17 or 18 amino acids. The positions of the cysteine residues, shown as C in Formula (1), are invariant in the peptides of the invention; however, in the modified forms of the peptides of Formula (1), also included within the scope of the invention, 1-4 of these cysteines may be replaced by a hydrophobic or small amino acid.

The amino terminus of the peptide may be in the free amino form or may be acylated by a group of the formula $RCO-$, wherein R represents a hydrocarbyl group of 1-6C. The hydrocarbyl group is saturated or unsaturated and is typically, for example, methyl, ethyl, i-propyl, t-butyl, n-pentyl, cyclohexyl, cyclohexene-2-yl, hexene-3-yl, hexyne-4-yl, and the like.

The C-terminus of the peptides of the invention may be in the form of the underivatized carboxyl group, either as the free acid or an acceptable salt, such as the potassium, sodium, calcium, magnesium, or other salt of an inorganic ion or of an organic ion such as caffeine. The carboxyl terminus may also be derivatized by formation of an ester with an alcohol of the formula ROH, or may be amidated by an amine of the formula NH_3 , or RNH_2 , or R_2NH , wherein each R is independently hydrocarbyl of 1-6C as defined above. Amidated forms of the peptides wherein the C-terminus has the formula $CONH_2$ are preferred.

As the peptides of the invention contain substantial numbers of basic amino acids, the peptides of the invention may be supplied in the form of the acid addition salts. Typical acid addition salts

include those of inorganic ions such as chloride, bromide, iodide, fluoride or the like, sulfate, nitrate, or phosphate, or may be salts of organic anions such as acetate, formate, benzoate and the like. The acceptability of each of such salts is dependent on the intended use, as is commonly understood.

The peptides of the invention that contain at least two cysteines may be in straight-chain or cyclic form. The straight-chain forms are convertible to the cyclic forms, and vice versa. Methods for forming disulfide bonds to create the cyclic peptides are well known in the art, as are methods to reduce disulfides to form the linear compounds. The linear compounds can be stabilized by addition of a suitable alkylating agent such as iodoacetamide.

The cyclic forms are the result of the formation of cystine linkages among all or some of the four invariant cysteine residues. Cyclic forms of the invention include all possible permutations of cystine bond formation; if the cysteines are numbered in order of their occurrence starting at the N-terminus as C₆, C₈, C₁₃ and C₁₅, these permutations include:

C₆-C₈;

C₆-C₁₃;

C₆-C₁₅;

C₈-C₁₃;

C₈-C₁₅;

C₁₃-C₁₅;

C₆-C₈, C₁₃-C₁₅;

C₆-C₁₃, C₈-C₁₅; and

C₆-C₁₅, C₈-C₁₃.

In the modified forms of the peptides, where 1-4 cysteines are replaced, similar permutations are available when 2-3 cysteines are present.

The native forms of the protegrins contain two cystine bonds are between the cysteine at position

6 and the cysteine at position 15 and the other between the cysteine at position 8 and the cysteine at position 13. Accordingly, in those embodiments having two cystine linkages, the C₆-C₁₅, C₈-C₁₃ form is preferred. However, it has been found by the present applicants that forms of the protegrins containing only one cystine linkage are active and easily prepared. Preferred among embodiments having only one cystine linkage are those represented by C₆-C₁₅ alone and by C₈-C₁₃ alone.

As the linearalized forms of the native cyclic peptides have valuable activities, even when chemically stabilized to preserve the sulfhydryl form of cysteine for example, by reaction with iodoacetamide, the compounds of the invention also include linearalized forms which are stabilized with suitable reagents. As defined herein, "SH-stabilized" forms of the peptides of the invention contain sulfhydryl groups reacted with standard reagents to prevent reformation into disulfide linkages.

An alternative approach to providing linear forms of the protegrins of the invention comprises use of the modified form of the peptides where cysteine residues are replaced by amino acids which do not form cystine linkages.

The amino acids denoted by A_n may be those encoded by the gene or analogs thereof, and may also be the D-isomers thereof. One preferred embodiment of the peptides of the invention is that form wherein all of the residues are in the D-configuration thus conferring resistance to protease activity while retaining antimicrobial or antiviral properties. The resulting protegrins are themselves enantiomers of the native L-amino acid-containing forms.

The amino acid notations used herein are conventional and are as follows:

	<u>Amino Acid</u>	<u>One-Letter Symbol</u>	<u>Three-letter Symbol</u>
	Alanine	A	Ala
	Arginine	R	Arg
5	Asparagine	N	Asn
	Aspartic acid	D	Asp
	Cysteine	C	Cys
	Glutamine	Q	Gln
	Glutamic acid	E	Glu
10	Glycine	G	Gly
	Histidine	H	His
	Isoleucine	I	Ile
	Leucine	L	Leu
	Lysine	K	Lys
15	Methionine	M	Met
	Phenylalanine	F	Phe
	Proline	P	Pro
	Serine	S	Ser
	Threonine	T	Thr
20	Tryptophan	W	Trp
	Tyrosine	Y	Tyr
	Valine	V	Val

The amino acids not encoded genetically are abbreviated as indicated in the discussion below.

In the specific peptides shown in the present application, the L-form of any amino acid residue having an optical isomer is intended unless the D-form is expressly indicated by a dagger superscript ([†]).

The compounds of the invention are peptides which are partially defined in terms of amino acid residues of designated classes. Amino acid residues can be generally subclassified into major subclasses as follows:

Acidic: The residue has a negative charge due to loss of H ion at physiological pH and the

residue is attracted by aqueous solution so as to seek the surface positions in the conformation of a peptide in which it is contained when the peptide is in aqueous medium at physiological pH.

5 Basic: The residue has a positive charge due to association with H ion at physiological pH and the residue is attracted by aqueous solution so as to seek the surface positions in the conformation of a peptide in which it is contained when the peptide is
10 in aqueous medium at physiological pH.

 Hydrophobic: The residues are not charged at physiological pH and the residue is repelled by aqueous solution so as to seek the inner positions in the conformation of a peptide in which it is contained
15 when the peptide is in aqueous medium.

 Neutral/polar: The residues are not charged at physiological pH, but the residue is not sufficiently repelled by aqueous solutions so that it would seek inner positions in the conformation of a peptide in which it is contained when the peptide is
20 in aqueous medium.

 This description also characterizes certain amino acids as "small" since their side chains are not sufficiently large, even if polar groups are lacking,
25 to confer hydrophobicity. "Small" amino acids are those with four carbons or less when at least one polar group is on the side chain and three carbons or less when not.

 It is understood, of course, that in a statistical collection of individual residue molecules some molecules will be charged, and some not, and there will be an attraction for or repulsion from an aqueous medium to a greater or lesser extent. To fit the definition of "charged," a significant percentage
30 (at least approximately 25%) of the individual
35 molecules are charged at physiological pH. The degree of attraction or repulsion required for classification

as polar or nonpolar is arbitrary and, therefore, amino acids specifically contemplated by the invention have been classified as one or the other. Most amino acids not specifically named can be classified on the basis of known behavior.

Amino acid residues can be further subclassified as cyclic or noncyclic, and aromatic or nonaromatic, self-explanatory classifications with respect to the side-chain substituent groups of the residues, and as small or large. The residue is considered small if it contains a total of four carbon atoms or less, inclusive of the carboxyl carbon, provided an additional polar substituent is present; three or less if not. Small residues are, of course, always nonaromatic.

For the naturally occurring protein amino acids, subclassification according to the foregoing scheme is as follows.

Acidic: Aspartic acid and Glutamic acid;

Basic:

Noncyclic: Arginine, Lysine;

Cyclic: Histidine;

Small: Glycine, Serine, Alanine, Threonine;

Polar/large: Asparagine, Glutamine;

Hydrophobic: Tyrosine, Valine, Isoleucine, Leucine, Methionine, Phenylalanine, Tryptophan.

The gene-encoded secondary amino acid proline is a special case due to its known effects on the secondary conformation of peptide chains, and is not, therefore, included in a group. Cysteine

residues are also not included in these classifications since their capacity to form disulfide bonds to provide secondary structure is critical in the compounds of the present invention.

5 Certain commonly encountered amino acids, which are not encoded by the genetic code, include, for example, beta-alanine (beta-Ala), or other omega-amino acids, such as 3-aminopropionic, 2,3-diaminopropionic (2,3-diaP), 4-aminobutyric and so
10 forth, alpha-aminisobutyric acid (Aib), sarcosine (Sar), ornithine (Orn), citrulline (Cit), t-butylalanine (t-BuA), t-butylglycine (t-BuG), N-methylisoleucine (N-MeIle), phenylglycine (Phg), and cyclohexylalanine (Cha), norleucine (Nle),
15 2-naphthylalanine (2-Nal); 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic); β -2-thienylalanine (Thi); methionine sulfoxide (MSO); and homoarginine (Har). These also fall conveniently into particular categories.


20 Based on the above definitions, Sar, beta-Ala, 2,3-diaP and Aib are small; t-BuA, t-BuG, N-MeIle, Nle, Mvl, Cha, Phg, Nal, Thi and Tic are hydrophobic; Orn and Har are basic;
25 Cit, Acetyl Lys, and MSO are neutral/polar. The various omega-amino acids are classified according to size as small (beta-Ala and 3-aminopropionic) or as large and hydrophobic (all others).

30 Other amino acid substitutions of those encoded in the gene can also be included in peptide compounds within the scope of the invention and can be classified within this general scheme according to their structure.

35 In all of the peptides of the invention, one or more amide linkages (-CO-NH-) may optionally be replaced with another linkage which is an isostere

such as $-\text{CH}_2\text{NH}-$, $-\text{CH}_2\text{S}-$, $-\text{CH}_2\text{CH}_2-$, $-\text{CH}=\text{CH}-$ (cis and trans), $-\text{COCH}_2-$, $-\text{CH}(\text{OH})\text{CH}_2-$ and $-\text{CH}_2\text{SO}-$. This replacement can be made by methods known in the art. The following references describe preparation of peptide analogs which include these alternative-linking moieties: Spatola, A.F., Vega Data (March 1983), Vol. 1, Issue 3, "Peptide Backbone Modifications" (general review); Spatola, A.F., in "Chemistry and Biochemistry of Amino Acids Peptides and Proteins," B. Weinstein, eds., Marcel Dekker, New York, p. 267 (1983) (general review); Morley, J.S., Trends Pharm Sci (1980) pp. 463-468 (general review); Hudson, D., et al., Int J Pept Prot Res (1979) 14:177-185 ($-\text{CH}_2\text{NH}-$, $-\text{CH}_2\text{CH}_2-$); Spatola, A.F., et al., Life Sci (1986) 38:1243-1249 ($-\text{CH}_2-\text{S}$); Hann, M.M., J Chem Soc Perkin Trans I (1982) 307-314 ($-\text{CH}-\text{CH}-$, cis and trans); Almquist, R.G., et al., J Med Chem (1980) 23:1392-1398 ($-\text{COCH}_2-$); Jennings-White, C., et al., Tetrahedron Lett (1982) 23:2533 ($-\text{COCH}_2-$); Szelke, M., et al., European Application EP 45665 (1982) CA:97:39405 (1982) ($-\text{CH}(\text{OH})\text{CH}_2-$); Holladay, M.W., et al., Tetrahedron Lett (1983) 24:4401-4404 ($-\text{C}(\text{OH})\text{CH}_2-$); and Hruby, V.J., Life Sci (1982) 31:189-199 ($-\text{CH}_2-\text{S}$).

The compounds of Formula (1) are generally defined as



and the N-terminal acylated and/or C-terminal amidated or esterified forms thereof, which is either in the optionally $-\text{SH}$ stabilized linear or in a cystine-bridged form

wherein each of A_1 and A_9 is independently a basic amino acid;

each of A_2 and A_3 is independently a small amino acid;

each of A_5 , A_7 , A_{12} , A_{14} and A_{16} is independently a hydrophobic amino acid;

each of A_4 and A_{10} is independently a basic or a small amino acid;

A_{11} is a basic or a hydrophobic amino acid;

5 A_{17} is not present or, if present, is a small amino acid;

A_{18} is not present or, if present, is a basic amino acid, or a

modified form of formula (1) and the N-terminal acylated and/or C-terminal amidated or esterified forms thereof wherein each of 1-4 cysteines is independently replaced by a hydrophobic amino acid or a small amino acid.

10 with the proviso that if said compound is of the formula

15 RGGRLCYCRRRFCVCVGR,
RGGRLCYCRRRFCICV,
RGGGLCYCRRRFCVCVGR, or
RGGRLCYCRGWICFCVGR

in the amidated and di-cystine-bridged form, said compound is purified and isolated.

20 In preferred embodiments of the compounds of the invention, each of A_1 and A_2 is independently selected from the group consisting of R, K and Har; more preferably, both A_1 and A_2 are R.

25 In another class of preferred embodiments, each of A_2 and A_3 is independently selected from the group consisting of G, A, S and T; more preferably, A_2 and A_3 are G.

30 In another set of preferred embodiments, A_4 is selected from the group consisting of R, K, Har, G, A, S and T; more preferably, A_4 is R or G.

35 In another set of preferred embodiments, each of A_5 , A_{14} and A_{16} is independently selected independently from the group consisting of I, V, L, Nle and F; preferably I, V, L and F.

In another set of preferred embodiments, each of A_7 and A_{12} is independently selected from the group

consisting of I, V, L, W, Y and F; preferably A₇ is Y and A₁₂ is I or F.

In another set of preferred embodiments, each of A₁₀ and A₁₁ is independently R, G or W.

5 A₁₇, when present, is preferably G, A, S or T, most preferably G;

A₁₈, when present, is preferably R, K or Har, most preferably R.

10 As described above, the compounds of Formula (1) are either in cyclic or noncyclic (linearalized) form or may be modified wherein 1-4 of the cysteines is replaced by a small amino acid residue or a basic amino acid residue. If the linearalized forms of the compound of Formula (1) are prepared, or if linearalized forms of those modified peptides which contain at least two
15 cysteines are prepared, it is preferred that the sulfhydryl groups be stabilized by addition of a suitable reagent. Preferred embodiments for the hydrophobic amino acid to replace cysteine residues are I, V, L and NLe, preferably I, V or L. Preferred small amino acids to
20 replace the cysteine residues include G, A, S and T, most preferably G.

In an alternative embodiment, the peptides of the invention are defined as described by Formula (1),
25 but wherein the definitions of A_n in each case are determined by the isolatability of the peptide from animal leukocytes by the invention method. The invention method comprises the steps of providing an ultrafiltrate of a lysate of animal leukocytes and isolating peptides
30 of 16-18 amino acids. These peptides can further be defined by the ability of DNA encoding them to hybridize under stringent conditions to DNA encoding the peptides exemplified as PG-1, PG-2, PG-3, and PG-4 herein.

35 Particularly preferred compounds of the invention are:

Unmodified forms

PG-1: R-G-G-R-L-C-Y-C-R-R-R-F-C-V-C-V-G-R

PG-2: R-G-G-R-L-C-Y-C-R-R-R-F-C-I-C-V

PG-3: R-G-G-G-L-C-Y-C-R-R-R-F-C-V-C-V-G-R

PG-4: R-G-G-R-L-C-Y-C-R-G-W-I-C-F-C-V-G-R

R-G-G-R-L-C-Y-C-R-R-R-F-C-V-C-V

5 K-G-G-R-L-C-Y-C-R-R-R-F-C-V-C-V

R-G-G-Har-L-C-Y-C-R-R-R-F-C-V-C-V

R-G-G-Har-L-C-Y-C-Har-R-R-F-C-V-C-V-G-R

R-G-G-R-V-C-Y-C-R-Har-R-F-C-V-C-V-G-R

R-G-G-R-L-C-Y-C-R-K-K-W-C-V-C-V-G-R

10 R-G-G-R-L-C-Y-C-R-Har-R-Y-C-V-C-V-G-R

R-G-S-G-L-C-Y-C-R-R-K-W-C-V-C-V-G-R

R-A-T-R-I-C-F-C-R-R-R-F-C-V-C-V-G-R

R-G-G-K-V-C-Y-C-R-Har-R-F-C-V-C-V-G-R

R-A-T-R-I-C-F-C-R†-R-R-F-C-V-C-V-G-R†

15 R-G-G-K-V-C-Y-C-R-Har†-R-F-C-V-C-V-G-R

PG-1: R-G-G-R-L-C-Y-C-R-R-R-F-C-V-C-V-G-R (all †)

PG-2: R-G-G-R-L-C-Y-C-R-R-R-F-C-I-C-V (all †)

PG-3: R-G-G-G-L-C-Y-C-R-R-R-F-C-V-C-V-G-R (all †)

PG-4: R-G-G-R-L-C-Y-C-R-G-W-I-C-F-C-V-G-R (all †)

20 both the linear and mono- and bicyclic forms thereof, and including the N-terminal acylated and C-terminal amidated forms;

Modified forms

R-G-G-R-L-V-Y-C-R-R-R-F-C-V-C-V-G-R

25 R-G-G-R-L-G-Y-C-R-R-R-F-C-I-C-V

R-G-G-G-L-C-Y-G-R-R-R-F-C-V-C-V-G-R

R-G-G-R-L-G-Y-G-R-R-R-F-G-V-C-V

K-G-G-R-L-V-Y-V-R-R-R-F-I-V-C-V

R-G-G-Har-L-C-Y-C-R-R-R-F-C-V-G-V

30 R-G-G-Har-L-C-Y-C-Har-R-R-F-C-V-L-V-G-R

R-G-G-R-V-C-Y-V-R-Har-R-F-L-V-G-V-G-R

R-G-G-R-L-C-Y-S-R-K-K-W-C-V-S-V-G-R

R-G-G-R-L-C-Y-C-R-Har-R-Y-S-V-V-V-G-R

R-G-S-G-L-S-Y-C-R-R-K-W-G-V-C-V-G-R

35 R-A-T-R-I-S-F-S-R-R-R-F-S-V-S-V-G-R

R-G-G-K-V-C-Y-G-R-Har-R-F-S-V-C-V-G-R

R-A-T-R-I-V-F-C-R†-R-R-F-G-V-C-V-G-R†

R-G-G-K-V-C-Y-L-R-Har†-R-F-L-V-C-V-G-R
both the linear and cyclic (where possible)
forms thereof, and including the N-terminal acylated and
C-terminal amidated forms.

5 Preparation of the Invention Compounds

 The invention compounds, often designated
herein "protegrins" are essentially peptide backbones
which may be modified at the N- or C-terminus and also
may contain one or two cystine disulfide linkages. The
10 peptides may first be synthesized in noncyclized form.
 These peptides may then be converted to the cyclic
peptides if desired by standard methods of cystine bond
formation. As applied to the protegrins herein, "cyclic
forms" refers to those forms which contain cyclic
15 portions by virtue of the formation of disulfide linkages
between cysteine residues in the peptide. If the
straight-chain forms are preferred, it is preferable to
stabilize the sulfhydryl groups for any peptides of the
invention which contain two or more cysteine residues.

20 Standard methods of synthesis of peptides
the size of protegrins are known. Most commonly used
currently are solid phase synthesis techniques; indeed,
automated equipment for systematically constructing
peptide chains can be purchased. Solution phase
25 synthesis can also be used but is considerably less
convenient. When synthesized using these standard
techniques, amino acids not encoded by the gene and
D-enantiomers can be employed in the synthesis. Thus,
one very practical way to obtain the compounds of the
30 invention is to employ these standard chemical synthesis
techniques.

 In addition to providing the peptide
backbone, the N- and/or C-terminus can be derivatized,
again using conventional chemical techniques. The
35 compounds of the invention may optionally contain an acyl
group, preferably an acetyl group at the amino terminus.

Methods for acetylating or, more generally, acylating, the free amino group at the N-terminus are generally known in the art; in addition, the N-terminal amino acid may be supplied in the synthesis in acylated form.

5 At the carboxy terminus, the carboxyl group may, of course, be present in the form of a salt; in the case of pharmaceutical compositions this will be a pharmaceutically acceptable salt. Suitable salts include those formed with inorganic ions such as NH_4^+ , Na^+ , K^+ ,
10 Mg^{++} , Ca^{++} , and the like as well as salts formed with organic cations such as those of caffeine and other highly substituted amines. The carboxy terminus may also be esterified using alcohols of the formula ROH wherein R is hydrocarbyl (1-6C) as defined above. Similarly, the
15 carboxy terminus may be amidated so as to have the formula $-\text{CONH}_2$, $-\text{CONHR}$, or $-\text{CONR}_2$, wherein each R is independently hydrocarbyl (1-6C) as herein defined. Techniques for esterification and amidation as well as neutralizing in the presence of base to form salts are
20 all standard organic chemical techniques.

 If the peptides of the invention are prepared under physiological conditions, the side-chain amino groups of the basic amino acids will be in the form of the relevant acid addition salts.

25 Formation of disulfide linkages, if desired, is conducted in the presence of mild oxidizing agents. Chemical oxidizing agents may be used, or the compounds may simply be exposed to the oxygen of the air to effect these linkages. Various methods are known in the art.
30 Processes useful for disulfide bond formation have been described by Tam, J.P. et al., Synthesis (1979) 955-957; Stewart, J.M. et al., "Solid Phase Peptide Synthesis" 2d Ed. Pierce Chemical Company Rockford, IL (1984); Ahmed A.K. et al., J Biol Chem (1975) 250:8477-8482 and
35 Pennington M.W. et al., Peptides 1990, E. Giralt et al., ESCOM Leiden, The Netherlands (1991) 164-166. An additional alternative is described by Kamber, B. et al.,

Helv Chim Acta (1980) 63:899-915. A method conducted on solid supports is described by Albericio Int J Pept Protein Res (1985) 26:92-97.

5 A particularly preferred method is solution oxidation using molecular oxygen. This method has been used by the inventors herein to refold synthetic PG-1, PG-3 in its amide or acid forms, enantioPG-1 and the two unisulfide PG-1 compounds (C₆-C₁₅ and C₈-C₁₃). Recoveries are as high as 30%.

10 If the peptide backbone is comprised entirely of gene-encoded amino acids, or if some portion of it is so composed, the peptide or the relevant portion may also be synthesized using recombinant DNA techniques. The DNA encoding the peptides of the invention may itself
15 be synthesized using commercially available equipment; codon choice can be integrated into the synthesis depending on the nature of the host. Alternatively, although less convenient, the DNA can be obtained, at least initially, by screening a cDNA library prepared
20 from porcine leukocytes using probes or PCR primers based on the sequences of the protegrins described herein. This results in recovery of the naturally occurring sequence encoding the protegrins of the invention. Obtention of this native sequence is significant for
25 purposes other than the synthesis of the protegrins per se; the availability of the naturally occurring sequences provides a useful probe to obtain corresponding DNA encoding protegrins of other species. Thus, cDNA libraries, for example, of leukocytes derived from other
30 animals can be screened using the native DNA, preferably under conditions of high stringency. High stringency is as defined by Maniatis, et al. Molecular Cloning: a Laboratory Manual 2nd Ed, Cold Spring Harbor Laboratory Press (1989), the relevant portions of which are
35 incorporated herein by reference. This procedure also permits recovery of allelic variants of these peptides from the same species.

Alternatively, the protegrins can be prepared by isolation from leukocytes of a desired species using techniques similar to those disclosed herein for the isolation of porcine protegrins. In general, these techniques involve preparing a lysate of a leukocyte preparation, ultrafiltering the supernatant of the clarified lysate and recovering the ultrafiltrate. The ultrafiltrate is then subjected to chromatographic separation. The location of fragments having antimicrobial and antiviral activity corresponding to protegrins can be assessed using criteria of molecular weight and assaying the fractions for the desired activities as described herein. The native forms of these peptides are believed to be the cyclic forms; if desired, the linearized forms can be prepared by treating the peptides with reducing agents and stabilizing the sulfhydryl groups that result.

Isolated and recombinantly produced forms of the protegrins may require subsequent derivatization to modify the N- and/or C-terminus and, depending on the isolation procedure, to effect the formation of cystine bonds as described hereinabove. Depending on the host organism used for recombinant production and the animal source from which the protein is isolated, some or all of these conversions may already have been effected.

For recombinant production, the DNA encoding the protegrins of the invention is included in an expression system which places these coding sequences under control of a suitable promoter and other control sequences compatible with an intended host cell. Types of host cells available span almost the entire range of the plant and animal kingdoms. Thus, the protegrins of the invention could be produced in bacteria or yeast (to the extent that they can be produced in a nontoxic or refractile form or utilize resistant strains) as well as in animal cells, insect cells and plant cells. Indeed, modified plant cells can be used to regenerate plants

containing the relevant expression systems so that the resulting transgenic plant is capable of self protection vis-à-vis these infective agents.

5 The protegrins of the invention can be produced in a form that will result in their secretion from the host cell by fusing to the DNA encoding the protegrin, a DNA encoding a suitable signal peptide, or may be produced intracellularly. They may also be produced as fusion proteins with additional amino acid
10 sequence which may or may not need to be subsequently removed prior to the use of these compounds as antimicrobials or antivirals.

Thus, the protegrins of the invention can be produced in a variety of modalities including chemical
15 synthesis, recombinant production, isolation from natural sources, or some combination of these techniques.

Those members of the protegrin class which occur naturally are supplied in purified and isolated form. By "purified and isolated" is meant free from the
20 environment in which the peptide normally occurs (in the case of such naturally occurring peptides) and in a form where it can be used practically. Thus, "purified and isolated" form means that the peptide is substantially pure, i.e., more than 90% pure, preferably more than 95%
25 pure and more preferably more than 99% pure or is in a completely different context such as that of a pharmaceutical preparation.

Antibodies

Antibodies to the protegrins of the
30 invention may also be produced using standard immunological techniques for production of polyclonal antisera and, if desired, immortalizing the antibody-producing cells of the immunized host for sources of monoclonal antibody production. Techniques for producing
35 antibodies to any substance of interest are well known. It may be necessary to enhance the immunogenicity of the

substance, particularly as here, where the material is only a short peptide, by coupling the hapten to a carrier. Suitable carriers for this purpose include substances which do not themselves produce an immune response in the mammal to be administered the hapten-carrier conjugate. Common carriers used include keyhole limpet hemocyanin (KLH), diphtheria toxoid, serum albumin, and the viral coat protein of rotavirus, VP6. Coupling of the hapten to the carrier is effected by standard techniques such as contacting the carrier with the peptide in the presence of a dehydrating agent such as dicyclohexylcarbodiimide or through the use of linkers such as those available through Pierce Chemical Company, Chicago, IL.

The protegrins of the invention in immunogenic form are then injected into a suitable mammalian host and antibody titers in the serum are monitored. It should be noted, however, that some forms of the protegrins require modification before they are able to raise antibodies, due to their resistance to antigen processing. For example, the native form of PG-1, containing two cystine bridges is nonimmunogenic when administered without coupling to a larger carrier and was a poor immunogen even in the presence of potent adjuvants and when coupled through glutaraldehyde or to KLH. Applicants believe this to be due to its resistance to attack by leukocyte serine proteases (human PMN elastase and cathepsin G) as well as to attack by an aspartic protease (pepsin) that resembles several macrophage cathepsins. The lack of immunogenicity may therefore result from resistance to processing to a linear form that can fit in the antigen-presenting pocket of the presenting cell. Immunogenicity of these forms of the protegrins can be enhanced by cleaving the disulfide bonds.

Polyclonal antisera may be harvested when titers are sufficiently high. Alternatively, antibody-

producing cells of the host such as spleen cells or peripheral blood lymphocytes may be harvested and immortalized. The immortalized cells are then cloned as individual colonies and screened for the production of the desired monoclonal antibodies.

The antibodies of the invention are, of course, useful in immunoassays for determining the amount or presence of the protegrins. Such assays are essential in quality controlled production of compositions containing the protegrins of the invention. In addition, the antibodies can be used to assess the efficacy of recombinant production of the protegrins, as well as screening expression libraries for the presence of protegrin encoding genes.

Compositions Containing the Protegrins and Methods of Use

The protegrins of the invention are effective in inactivating a wide range of microbial and viral targets, including gram-positive and gram-negative bacteria, yeast, protozoa and certain strains of virus. Accordingly, they can be used in disinfectant compositions and as preservatives for materials such as foodstuffs, cosmetics, medicaments, or other materials containing nutrients for organisms. For use in such contexts, the protegrins are supplied either as a single protegrin, in admixture with several other protegrins, or in admixture with additional antimicrobial agents. In general, as these are preservatives in this context, they are usually present in relatively low amounts, of less than 5%, by weight of the total composition, more preferably less than 1%, still more preferably less than 0.1%.

The peptides of the invention are also useful as standards in antimicrobial assays and in assays for determination of capability of test compounds to bind to endotoxins such as lipopolysaccharides.

For use as antimicrobials or antivirals for treatment of animal subjects, the protegrins of the invention can be formulated as pharmaceutical or veterinary compositions. Depending on the subject to be treated, the mode of administration, and the type of treatment desired -- e.g., prevention, prophylaxis, therapy; the protegrins are formulated in ways consonant with these parameters. A summary of such techniques is found in Remington's Pharmaceutical Sciences, latest edition, Mack Publishing Co., Easton, PA.

The protegrins are particularly attractive as an active ingredients pharmaceutical compositions useful in treatment of sexually transmitted diseases, including those caused by *Chlamydia trachomatis*, *Treponema pallidum*, *Neisseria gonorrhoeae*, *Trichomonas vaginalis*, Herpes simplex type 2 and HIV. Topical formulations are preferred and include creams, salves, oils, powders, gels and the like. Suitable topical excipient are well known in the art and can be adapted for particular uses by those of ordinary skill.

In general, for use in treatment or prophylaxis of STDs, the protegrins of the invention may be used alone or in combination with other antibiotics such as erythromycin, tetracycline, macrolides, for example azithromycin and the cephalosporins. Depending on the mode of administration, the protegrins will be formulated into suitable compositions to permit facile delivery to the affected areas. The protegrins may be used in forms containing one or two disulfide bridges or may be in linear form. In addition, use of the enantiomeric forms containing all D-amino acids may confer advantages such as resistance to those proteases, such as trypsin and chymotrypsin, to which the protegrins containing L-amino acids are less resistant.

The protegrins of the invention can be administered singly or as mixtures of several protegrins or in combination with other pharmaceutically active components. The formulations may be prepared in a manner
5 suitable for systemic administration or topical or local administration. Systemic formulations include those designed for injection (e.g., intramuscular, intravenous or subcutaneous injection) or may be prepared for
transdermal, transmucosal, or oral administration. The
10 formulation will generally include a diluent as well as, in some cases, adjuvants, buffers, preservatives and the like. The protegrins can be administered also in liposomal compositions or as microemulsions.

If administration is to be oral, the
15 protegrins of the invention must be protected from degradation in the stomach using a suitable enteric coating. This may be avoided to some extent by utilizing amino acids in the D-configuration, thus providing
resistance to protease. However, the peptide is still
20 susceptible to hydrolysis due to the acidic conditions of the stomach; thus, some degree of enteric coating may still be required.

As described in the examples below, the
peptides of the invention retain their activity against
25 microbes in the context of borate solutions that are commonly used in eye care products. It has also been shown that when tested for antimicrobial activity against *E. coli* in the presence and absence of lysozyme in borate buffered saline, that the presence of lysozyme enhanced
30 the effectiveness of PG-3. This effect was more pronounced when the PG-3 was autoclaved and similar patterns were obtained for both the free-acid form and the amide. Accordingly, the protegrins may be used as
preservatives in such compositions or as antimicrobials
35 for treatment of eye infections.

It is particularly important that the protegrins retain their activity under physiological

conditions including relatively high saline and in the presence of serum. In addition, the protegrins are not cytotoxic with respect to the cells of higher organisms. These properties, described herein below in the Examples, make them particularly suitable for *in vivo* and therapeutic use.

The protegrins of the invention may also be applied to plants or to their environment to prevent viral- and microbial-induced diseases in these plants. Suitable compositions for this use will typically contain a diluent as well as a spreading agent or other ancillary agents beneficial to the plant or to the environment.

Thus, the protegrins of the invention may be used in any context wherein an antimicrobial and/or antiviral action is required. This use may be an entirely *in vitro* use, or the peptides may be administered to organisms.

In addition, the antimicrobial or antiviral activity may be generated *in situ* by administering an expression system suitable for the production of the protegrins of the invention. Such expression systems can be supplied to plant and animal subjects using known techniques. For example, in animals, pox-based expression vectors can be used to generate the peptides *in situ*. Similarly, plant cells can be transformed with expression vectors and then regenerated into whole plants which are capable of their own production of the peptides.

A particularly useful property of the protegrins is their activity in the presence of serum. Unlike defensins, protegrins are capable of exerting their antimicrobial effects in the presence of serum.

As shown hereinbelow, the protegrins are capable of inactivating endotoxins derived from gram-negative bacteria -- i.e., lipopolysaccharides (LPS) -- in standard assays. Accordingly, the protegrins may be used under any circumstances where inactivation of LPS is

desired. One such situation is in the treatment or amelioration of gram-negative sepsis.

The protegrins of the invention, therefore, represent a peculiarly useful class of compounds because of the following properties:

1) they have an antimicrobial effect with respect to a broad spectrum of target microbial systems, including viruses, including retroviruses, bacteria, fungi, yeast and protozoa.

2) Their antimicrobial activity is effective under physiological conditions - i.e., physiological saline and in the presence of serum.

3) They are not toxic to the cells of higher organisms.

4) They can be prepared in nonimmunogenic form thus extending the number of species to which they can be administered.

5) They can be prepared in forms which are resistant to certain proteases suggesting they are antimicrobial even in lysosomes.

6) They can be prepared in forms that resist degradation when autoclaved, thus simplifying their preparation as components of pharmaceuticals.

The following examples are intended to illustrate but not to limit the invention.

Example 1

Isolation of PG-1, PG-2 and PG-3

Fresh porcine blood was collected into 15-liter vessels containing 5% EDTA in normal saline, pH 7.4 as an anticoagulant (33 ml/liter blood). The blood cells were allowed to sediment for 90 minutes at room temperature and the leukocyte-rich supernatant was removed and centrifuged at 200 x g for 5.7 minutes. The pellets were pooled and suspended in 0.84% ammonium chloride to lyse erythrocytes and the resulting leukocytes (70-75% PMN, 5-10% eosinophils, 15-25%

lymphocytes and monocytes) were washed in normal saline, resuspended in ice-cold 10% acetic acid at 10^8 /ml, homogenized and stirred overnight at 4°C. The preparation was centrifuged at 25,000 x g for 3 hours at 4°C and the supernatant was lyophilized and weighed.

950 mg (dry weight) of lyophilized extract, which contained 520 mg protein by BCA analysis, was stirred overnight at 4°C in 100 ml of 10% acetic acid and then centrifuged at 25,000 x g for 2 hours. The supernate was removed and passed by pressure through a 50 ml stirred ultracentrifugation cell (Amicon, Danvers MA) that contained a YM-5 filter. The ultrafiltrate (24.5 mg protein by BCA) was concentrated to 3 ml by vacuum centrifugation (SpeedVac Concentrator, Savant Instruments, Hicksville, NY), applied to a 2.5 x 117 cm BioGel P10 column (Bio-Rad, Hercules, CA) and eluted at 4°C with 5% acetic acid.

Fractions containing 6.6 ml were obtained. Fractions were assayed by absorption at 280 nm and the elution pattern is shown in Figure 1.

Aliquots (66 μ l) of each fraction were dried by vacuum centrifugation and resuspended in 6.6 μ l of 0.01% acetic acid. Five μ l samples of this concentrate were tested for antimicrobial activity against *E. coli* ML-35, *L. monocytogenes*, strain EGD and *C. albicans*, strain 820, using radiodiffusion and gel overlay techniques as described by Lehrer, R.I. et al. J Immunol Meth (1991) 137:167-173. Briefly, the underlay agars used for all organisms had a final pH of 6.5 and contained 9 mM sodium phosphate/1 mM sodium citrate buffer, 1% w/v agarose and 0.30 μ g/ml tryptocase soy broth powder (BBL Cockeysville, MD). The units of activity in the radial diffusion assay were measured as described; 10 units correspond to a 1 mm diameter clear zone around the sample well. Activities obtained for the various fractions are shown in Figure 2. Activity was found in a large number of fractions.

The active fractions were further examined by acid-urea PAGE (AU-PAGE) and SDS PAGE. Results of these analyses showed that active antimicrobial peptides of the appropriate molecular weight were present and concentrated in fractions 76-78.

Fractions 76-78 from the Biogel P10 column were then pooled and chromatographed on a 1 x 25 cm Vydac 218 TP1010 column with a gradient (buffer A is 0.1% TFA; buffer B is 0.1% TFA in acetonitrile) the increase in acetonitrile concentration was 1% per minute. The results, assessed in terms of absorbance at 280 nm and at 225 nm are shown in Figure 3. The peaks corresponding the three peptides illustrated herein are labeled in the figure. The figure also contains an inset which shows the results of an acid-urea PAGE gel stained with Comassie Blue that contains a starting mixture composed of the pooled fractions and the individual PG species. These are labeled M, 1, 2 and 3 on the inset. The results clearly show the presence of three distinct proteins.

The isolated proteins were subjected to amino acid analysis using three independent methods, and to Edman degradation, chymotrypsin digestion, and fast atom bombardment mass spectrometric analysis. The peptides, named "protegrins", are shown to have the amino acid sequences as follows:

PG-1: RGGRLCYCRRRFCVCVGR

PG-2: RGGRLCYCRRRFCICV

PG-3: RGGGLCYCRRRFCVCVGR,

and are amidated at the C-terminus.

The amidation status of the isolated peptides was established by synthesis of PG-3 both in the free carboxyl and carboxyamidated forms. These synthetic peptides were then compared to isolated PG-3 using AU-PAGE and also using reverse-phase HPLC. In both cases, the native product comigrated with the synthetic amidated form.

The location of the disulfide linkages in the isolated protegrins was also studied using PG-2 as a model. The determination was performed using sequential enzyme digestion (chymotrypsin followed by thermolysin) with direct analysis using LC-ESI-MS on the fragments obtained. The results of these analyses showed that the two intramolecular disulfide bonds were C₆-C₁₅ and C₈-C₁₃. With the location of the disulfides in these positions, the protegrin molecules are likely to exist as anti-parallel β sheets similar to the tachyplesins in overall conformation.

The antimicrobial proteins above are present in much lower concentrations in initial extracts than are the rabbit defensins in corresponding crude extracts where the defensins constitute more than 15% of the total protein in rabbit granulocytes. Using the AU-PAGE analytical method on the various stages of purification, the peptides are only faintly visible in the crude extracts, whereas corresponding crude extracts of rabbit granulocytes clearly show the presence of the defensins. The peptides of the invention become clearly evident only after the ultrafiltration step.

Because the protegrins whose structures are set forth above show sequence homology to the decapeptide region corresponding to residues 1-10 of rabbit defensin NP-3a in the decapeptide region at positions 4-13 of PG-3, the protegrins, and in particular PG-3, may share the property of defensin NP-3a in being capable of competitively antagonizing ACTH-mediated steroid synthesis by adrenocytes. This property, called "corticostasis", may influence the effectiveness of the protegrins as antiinfectious agents when employed in vivo.

Example 2Antimicrobial Activity

The radial diffusion assay in agarose gels described in Example 1 was also used to test the activity of the purified protegrins. Figures 4a, 4b and 4c show the results against three test organisms in units described as above. The rabbit defensin (NP-1) and the human defensin (HNP-1) were used as controls.

Figure 4a shows that PG-1 and PG-3 are more effective against *E. coli* ML-35P than HNP-1 and only slightly less effective than NP-1. PG-1 and PH-3 were also effective against *Listeria monocytogenes*, strain EGD as shown in Figure 4b. In Figure 4c, PG-1 and PG-3 were also shown effective against *Candida albicans*. In general, these peptides are approximately as effective as rabbit defensin NP-1 on a weight basis and are more effective than HNP-1. In all cases, PG-2 was also effective against the three organisms tested but was not as active as the other two peptides.

In addition to its activity in inhibiting the growth of the above-mentioned organisms, the PG-1 of the invention has been shown directly to inhibit the growth of *Staphylococcus aureus* (see Figure) and *K. pneumoneae* 270 (Figure). HNP-1 used as a control was less effective against *S. aureus* and almost entirely ineffective against *K. pneumoneae*.

The protegrins of the invention have also been tested against various other organisms and show broad spectrum activity. In addition to their effectiveness in inhibiting the growth of or infection by microorganisms associated with STDs as described in Example 9 hereinbelow, the protegrins show strong activity against the following microorganisms in addition to those tested hereinabove: *Pseudomonas aeruginosa*, *Klebsiella pneumoniae*, *Salmonella typhimurium*, *Staphylococcus aureus*, *Histoplasma capsulatum*, *Mycobacterium avium-intracellulare*, and *Mycobacterium*

tuberculosis. The protegrins showed only fair activity against *Vibrio vulnificus* and were inactive against *Vibrio cholerae* and *Borrelia burgdorferi*.

Example 3

5 Retention of Activity Under Certain Conditions

The antimicrobial activity of the invention compounds was tested as set forth above, but under conditions of 100 μ M NaCl and in the presence of 90% fetal calf serum. Figures 5a and 5b show --that PG-1 and PG-3
10 retain their activity with respect to *C. albicans* and *E. coli* respectively, even in the presence of 100mM NaCl. Neither NP-1 nor HNP-1 have this property. Figure 5c shows that although NP-1 and NHP-2 lose their ability to inactivate *C. albicans* in 90% fetal calf serum,
15 inactivation by PG-3 is retained.

Accordingly, the protegrins of the invention retain their antimicrobial properties under useful physiological conditions, including isotonic and borate solutions appropriate for use in eye care products.

20 In addition, synthetic PG-1 was tested with respect to its activity against *E. coli* ML-35 (serum sensitive) in underlayered gels containing only 10 mM sodium phosphate buffer, pH 7.4 and a 1:100 dilution of trypticase soy broth, both in the presence and absence of
25 2.5% normal human serum, which is below the lytic concentration for this strain of *E. coli*. In the presence of serum, the minimal bacteriocidal concentration was reduced from approximately 1.0 μ g/ml to about 0.1 μ g/ml. This type of effect was not observed
30 either for a linear fragment of cathepsin G or for the defensin HNP-1.

Similarly, using *C. albicans* as a target organism, underlayers were prepared with 10 mM sodium phosphate with and without 10% normal human serum. The
35 minimal fungicidal concentration fell from about 1.3 μ g/ml in the absence of serum to 0.14 μ g/ml in its

presence. The serum itself at this concentration did not effect *C. albicans*.

Thus, not only is the action of the protegrins not inhibited by the presence of serum, it is enhanced thereby. Similar results were obtained using *L. monocytogenes* as the target organism.

The protegrins PG-1 and PG-3 were incubated for 4 hours at pH 2.0 with 0.5 µg/ml pepsin and then neutralized. The residual antimicrobial activity against *C. albicans*, *E. coli* and *L. monocytogenes* was assessed and found to be fully retained. Similar experiments show that these compounds are not degraded by human leukocyte elastase or by human leukocyte cathepsin G even when exposed to high concentrations of these enzymes and at a pH of 7.0 - 8.0 favorable for proteolytic activity. In addition, synthetic PG-3 amide and synthetic PG-3 acid were autoclaved and tested for antimicrobial activity against *E. coli*, *L. monocytogenes* and *C. albicans*; retaining full antimicrobial activity in all cases. It is possible that the stability of these compounds to protease degradation and to autoclaving is enhanced by the presence of disulfide bonds.

Example 4

Ability to Bind Endotoxin

The protegrins of the invention were tested for their ability to bind the lipid polysaccharide (LPS) of the gram-negative bacterium *E. coli* strain 0.55B5. The assay was the *Limulus* amoebocyte lysate (LAL) test for endotoxins conducted in the presence and absence of the test compounds. The test was conducted using the procedure described in Sigma Technical Bulletin No. 210 as revised in December 1992 and published by Sigma Chemical Company, St. Louis, MO.

The LAL test is based on the ability of LPS to effect gelation in the commercial reagent E-Toxate™ which is prepared from the lysate of circulating

amebocytes of the Horseshoe Crab *Limulus polyphemus*. As described in the technical bulletin, when exposed to minute quantities of LPS, the lysate increases in opacity as well as viscosity and may gel depending on the concentration of endotoxin. The technical bulletin goes on to speculate that the mechanism appears analogous to the clotting of mammalian blood and involves the steps of activation of a trypsin-like preclotting enzymes by the LPS in the presence of calcium ion, followed by enzymic modifications of a "coagulogen" by proteolysis to produce a clottable protein. These steps are believed tied to the biologically active or "pyrogenic" portion of the molecule. It has been shown previously that detoxified LPS (or endotoxin) gives a negative LAL test.

The test compounds were used at various concentrations from 0.25 μg -10 μg in a final volume of 0.2 ml and the test mixtures contained LPS at a final concentration of 0.05 endotoxin unit/ml and E-Toxate" at the same concentration. The test compounds were incubated together with the LPS for 15 minutes before the E-Toxate" was added to a final volume after E-Toxate" addition of 0.2 ml. The tubes were then incubated for 30 minutes at 37°C and examined for the formation of a gel.

Both isolated native protegrins (nPGs) and synthetically prepared protegrins (sPGs) were tested. The sPGs were prepared with a carboxyl group at the C-terminus or with an amidated C-terminus. The nPGs are amidated at the C-terminus. Also tested were six different rabbit defensins (NPs) and four native human defensins (HNPs). The results are shown in Table 1.

Table 1

Peptide	10 μ g	5 μ g	2.5 μ g	1.0 μ g	0.5 μ g	0.25 μ g
nPG-1	no gel	no gel	no gel	no gel	+	++
nPG-2	no gel	no gel	no gel	no gel	+	++
nPG-3	no gel	no gel	trace	++	++	++
sPG-3 acid	no gel	no gel	trace	++	++	++
sPG-3 amide	no gel	no gel	no gel	+	++	++
NP-1	not tested	not tested	++	++	++	++
NP-2	trace	+	+	++	++	++
NP-3a	no gel	no gel	no gel	++	++	++
NP-3b	no gel	no gel	+	++	++	++
NP-4	not tested	not tested	+	++	++	++
NP-5	no gel	trace	+	+	++	++
HNP-1	no gel	+	+	++	++	++
HNP-2	trace	trace	trace	+	+	++
HNP-3	no gel	+	+	++	++	++
HNP-4	no gel	trace	trace	++	+	++

As seen from the results, all of the protegrins, both synthetic and native, and both in the amidated and nonamidated forms are able to bind sufficiently to LPS to prevent any substantial gel formation at concentrations as low as 2.5 $\mu\text{g}/0.2\text{ ml}$. nPG-1 and nPG-2 are effective at somewhat lower concentrations. The protegrins were substantially more effective than the NP or HNP test compounds; the most effective among these controls was NP-3a, a peptide whose primary sequence most closely resembles that of the protegrins.

In a follow-up experiment, the concentration of LPS was varied from 0.05-0.25 endotoxin units (E.U.) and synthetic PG-3 amide was used as the test compound. The results are shown in Table 2.

Table 2

Endotoxin Units	0.25 E.U.	0.10 E.U.	0.05 E.U.
sPG-3 amide (2.5 μg)	no gel	no gel	no gel
sPG-3 amide (1.0 μg)	no gel	no gel	no gel
sPG-3 amide (0.5 μg)	++	++	no gel
no added protein	++	++	++

These results show that since inhibition of gelation can be overcome by increasing the concentration of LPS, interaction with LPS is responsible for the lack of gelation, rather than interfering with the gelation enzyme cascade.

Example 5

Activity of Linearized Forms

nPG-1 and nPG-3 were converted to linear form using a reducing agent to convert the disulfide linkages to sulfhydryl groups, which were then stabilized by alkylating with iodoacetamide.

The ability of both cyclic and linearized PG-1 and PG-3 to inhibit gelation in the standard LAL assay was assessed then as described in Example 4 and the results are shown in Table 3.

Table 3

Peptide	5 μ g	2.5 μ g	1.0 μ g	0.25 μ g	.
nPG-1	no gel	no gel	++	++	++
cam-nPG-1	no gel	no gel	++	++	++
nPG-3	no gel	no gel	++	++	++
cam-nPG-3	no gel	no gel	++	++	++

These results show that the linearized and cyclic forms of the protegrins are equally capable of inhibiting gelation and binding to endotoxin.

The antimicrobial activity of the linearized forms was also compared with that of the native protegrins. Both linearized and cyclic forms of the protegrins tested continue to show antimicrobial activity, although the effectiveness of these peptides as antimicrobials depends on the nature of the target organism and on the test conditions. The antimicrobial activity of native PG-1 and its linearized form (cam-PG-1) and PG-3 and its linearized form (cam-PG-3) were tested according to the procedure set forth in Example 1 as described by Lehrer, R.I. et al. J Immunol Meth (1991) 137:167-173. The results are set forth in Figures 6a-6f.

Figures 6a and 6b show the antimicrobial activity of these peptides in the concentration range 20 μ g/ml-125 μ g/ml with respect to *E. coli* ML-35P either in 10 mM phosphate-citrate buffer, pH 6.5 (Figure 6a) or in the presence of this buffer plus 100 mM NaCl (Figure 6b). Both protegrins showed strong antimicrobial activity with respect to this organism; the linear form was slightly more potent in the presence of buffer alone than was the

cyclic form; on the other hand, the cyclic form was more potent than the linear form under isotonic conditions.

Figures 6c and 6d show the antimicrobial effect with respect to *L. monocytogenes*. In Figure 6c where the above-mentioned buffer alone was used, both cyclic and linearized forms of the protegrins showed strong antimicrobial activity and both were approximately equally effective over the concentration range tested (20 $\mu\text{g/ml}$ -125 $\mu\text{g/ml}$).

Figure 6d shows the effect with respect to *L. monocytogenes* in the presence of this buffer plus 100 mM NaCl over the same concentration range. The cyclic form retained strong antimicrobial activity with a slightly greater concentration dependence.

Linearization appeared to lower the activity appreciably although high concentrations were still able to show an antimicrobial effect.

The yeast *C. albicans* was tested with the results shown in Figures 6e and 6f. Figure 6e shows that all forms of these protegrins were antimicrobial in a dose-dependent manner over the above concentration range when tested in the presence of 10 mM phosphate buffer alone, although the linearized peptides were very slightly less effective. Figure 6f shows the results of the same assay run in the presence of buffer plus 100 mM NaCl. While the cyclized forms retained approximately the same level of antimicrobial effect, the activity of the linearized forms was greatly diminished so that at concentrations below 100 $\mu\text{g/ml}$ of the protegrin, virtually no antimicrobial effect was seen. However, at higher concentrations of 130 $\mu\text{g/ml}$, a moderate antimicrobial effect was observed.

Thus, depending on the target microorganism and the conditions used, both the cyclized and linearized forms of the protegrins have antimicrobial activity.

Example 6Antimicrobial Activity Under ConditionsSuitable for Treatment of the Eye

Contact lens solutions are typically formulated with borate buffered physiological saline and may or may not contain EDTA in addition. Protegrins in the form of the synthetic PG-3 amide and synthetic PG acid were tested generally in the assay described in Example 1 wherein all underlay gels contain 25 mM borate buffer, pH 7.4, 1% (v/v) tryptocase soy broth (0.3 µg/ml TSB powder) and 1% agarose. Additions included either 100 mM NaCl, 1 mM EDTA or a combination thereof. Other test compounds used as controls were the defensin NP-1 and lysozyme. Dose response curves were determined. Table 4 shows the estimated minimal bacteriocidal concentrations in µg/ml of the various test compounds.

Table 4

ESTIMATED MINIMAL FUNGICIDAL CONCENTRATIONS (µg/ml)				
Peptide	buffer	+ EDTA	+ NaCl	+ EDTA & NaCl
SPG-3 amide	13.0	9.5	4.1	3.1
SPG-3 acid	15.0	9.5	4.6	3.7
NP-1	35.0	45.0	>200	>200
lysozyme	75.0	45.0	>200	>200

Although protegrins are somewhat less active in 25 mM borate buffered saline than in 25 mM phosphate buffer, the antimicrobial activity is enhanced by adding physiological saline and modestly enhanced by 1 mM EDTA, as shown in the table. A similar test was run with *Candida albicans* as the target organism with the results shown in Table 5, which also shows estimates of minimal fungicidal concentrations.

Table 5

ESTIMATED MINIMAL FUNGICIDAL CONCENTRATIONS ($\mu\text{g/ml}$)			
Peptide	25 mM borate buffer	borate buffer +120 mM NaCl	borate buffer +EDTA & NaCl
nPG-3	32.0	9.0	8.0
sPG-3 amide	19.0	7.7	7.0
sPG-3 acid	19.0	9.2	9.3
NP-1	23.0	60.0	65.0
HNP-1	25.0	>200	>200

Table 6 shows results of similar experiments conducted with *L. monocytogenes* as the target.

Table 6

ESTIMATED MINIMAL BACTERICIDAL CONCENTRATIONS ($\mu\text{g/ml}$)			
Peptide	25 mM borate buffer	borate buffer +120 mM NaCl	borate buffer +EDTA & NaCl
nPG-3	25.0	7.0	5.7
sPG-3 amide	21.0	5.7	5.2
sPG-3 acid	30.0	7.0	7.0
NP-1	20.0	11.0	3.8
HNP-1	11.0	>200	>200

The results shown indicate that these compounds are capable of exerting their antimicrobial effects under conditions typically associated with conditions suitable for eye care products.

Example 7

Recovery of cDNA Clones and of a

New Protegrin-Encoding cDNA

cDNA Generation and PCR Amplification.

Total RNA was extracted from the bone marrow cells of a young red Duroc pig with guanidinium thiocyanate.

One μ g of total RNA was used to synthesize the first strand cDNA, with 20 pmol Oligo(dT) primer and 200 U Moloney-murine leukemia virus (M-MLV) reverse transcriptase (Clontech Laboratory, Palo Alto, CA) in a total reaction volume of 20 μ l. Two PCR primers were prepared. The sense primer (5'-GTCGGAATTCATGGAGACCCAGAG (A or G) GCCAG-3') corresponded to the 5' regions of PG-2 and PR-39 cDNA and contained an EcoRI restriction site. The antisense primer (5'-GTCGTCTAGA (C or G) GTTTCACAAGAATTTATTT-3') was complementary to 3' ends of PG-2 and PR-39 cDNA immediately preceding their poly A tails and contained an XbaI restriction site. PCR was carried out in a 50 μ l volume using 1/10 volume of the above pig cDNA as template, 25 pmol primers and 2.5 units of AmpliTaq DNA polymerase (Perkin Elmer-Cetus). The reaction was run for 30 cycles, with 1 min denaturation (94°C) and annealing (60°C) steps and a 2 min extension step (72°C) per cycle.

cDNA Cloning and Sequencing. The amplified cDNA was fractionated by preparative agarose electrophoresis and stained with ethidium bromide. The main fragment was cut out, digested with EcoR I and Xba I endonucleases (New England Biolabs, Beverly, MA), subcloned into a M13mp18 bacteriophage vector, and transformed into *E. coli* XL1-Blue MRF' competent cells (Stratagene, La Jolla, CA). DNA sequencing was performed with a kit (U.S. Biochemical Corp., Cleveland, OH). Nucleotide and protein sequences were analyzed with PC-GENE (Intelligenetics, Palo Alto, CA).

Northern blots. Ten μ g of total RNA was denatured in 50% formamide, separated by electrophoresis through 1% agarose gels in 0.62 M formaldehyde, and blotted onto GeneScreen Plus membranes (DuPont, Boston, MA) by capillary transfer.

The membrane was baked at 80°C for 2 h, and hybridized with ³²P-labeled probe in rapid hybridization buffer (Amersham, Arlington Height, IL).

The results of sequencing the various clones encoding the various protegrins is summarized in Figure 7. The cDNA sequences of protegrins PG-1, PG-3 and PG-4 contain 691 bases as had previously been shown for PG-2 by Storici, P. et al. Biochem Biophys Res Comm (1993) 196:1363-1368. The cDNAs show an upstream sequence encoding 110 amino acids which appears identical for all protegrins. Additional differences which are quite slight in nature are shown in Figure 7.

The analysis showed the presence of an additional protegrin having an amino acid sequence of Formula (1) wherein A₁₀ is a small amino acid and A₁₁ is a hydrophobic amino acid as distinguished from the previously known protegrins where these residues are basic. The amino acid sequence of PG-4 is therefore RGGRLCYCRGWICFCVGRG, wherein 1, 2, or 3 amino acids at the N-terminus may be deleted.

Figure 8 shows a comparison of the amino acid sequences of the four protegrins found so far in porcine leukocytes. There is complete homology in positions 1-3, 5-9, 13 and 15-16.

Additional clones were obtained by amplifying reverse transcribed porcine bone cell RNA using an upstream primer that corresponds to the 5' end of PG-2 and another cathelin-associated peptide, PR39, (Agerbeth B et al., Eur J Biochem (1991) 202:849-854; Storici, P et al., Biochem Biophys Res Com (1993) 186:1058-1065) and downstream primer that matches the region immediately preceding the poly A region. The resulting approximately 0.7 kb PCR product was subcloned into M13mp18 and recombinant plaques were chosen for purification and sequencing. In this manner, the sequences for the precursors of

PG-1, PG-3 and PG-4 were recovered. All of these peptides are encoded by a nucleotide sequence which encodes a precursor containing additional amino acid sequence upstream of A₁ of the compound of formula 1 (as shown for PG-4 in Figure 7).

Example 8

Preparation of EnantioPG-1

Using standard solid phase techniques, a protegrin having the amino acid sequence of PG-1, but wherein every amino acid is in the D form was prepared. This form of protegrin was tested against *E. coli*, *L. monocytogenes*, *C. albicans* and other microbes in the absence and presence of protease and otherwise as described for the radiodiffusion assay in agarose gels set forth in Example 1. The results are shown in Figures 9a-9g.

Figure 9a shows that both native PG-1 and enantioPG-1 in the absence of protease are equally effective in inhibiting the growth of *E. coli*. Figure 9b shows that neither trypsin nor chymotrypsin inhibits the antibacterial effect of enantioPG-1. Figure 9c shows that in the presence of these proteolytic enzymes, the ability of native PG-1 to inhibit the growth of *L. monocytogenes* is adversely affected, although, as shown in Figure 9d, in the absence of these proteases PG-1 is comparably active to an enantioPG-1.

Example 9

Activity of the Protegrins Against STD Pathogens

Table 7 summarizes the activity of the protegrin PG-1 as compared to the defensin HNP-1 against growth of STD pathogens. In these results, "active" means that the peptide was effective at less than 10 µg/ml; moderately active indicates that it was active at 10-25 µg/ml; and slightly active means

activity at 25-50 $\mu\text{g/ml}$. If no effect was obtained at 50-200 $\mu\text{g/ml}$ the compound was considered inactive.

Table 7

Activity against human STD pathogens	Protegrin PG-1	Defensin HNP-1
HIV-1	Active	Slightly active
<i>Chlamydia trachomatis</i>	Active	Slightly active
<i>Treponema pallidum</i>	Active	Inactive
<i>Neisseria gonorrhoeae</i>	Active	Inactive
<i>Trichomonas vaginalis</i>	Moderately active	Inactive
Herpes simplex type 2	Moderately active	Slightly active
Herpes simplex type 1	Inactive	Slightly active
<i>Hemophilus ducreyi</i>	Not tested	Not tested
Human papilloma virus	Not tested	Not tested

Chlamydia trachomatis

Unlike other bacteria associated with STDs, *Chlamydia* requires an intracellular habitat for metabolic activity and binary fission. The life cycle is as follows: there is an extracellular form which is a metabolically inactive particle somewhat sporelike in its behavior, referred to as an elementary body (EB). The EB attaches to the host cell and is ingested to form an internal vacuolar space often called an "inclusion". The bacterium reorganizes to the delicate reticulate body (RB) which is noninfective but metabolically active and which over a 48-72 hour period undergoes reformation to the EB state. The EBs are then released from the cell. Rather than a peptidoglycan layer, *Chlamydia* contains multiple disulfide linkages in cysteine-rich proteins for protection in the EB stage.

The protegrins of the invention were tested for their antimicrobial activity against *Chlamydia* using the "gold standard" chlamydial culture system for clinical specimens described by Clarke, L.M. in Clinical Microbiology Procedures Handbook II (1992), Isenberg, H.T. Ed. Am. Soc. Microbiol. Washington, D.C.; pp. 8.0.1 to 8.24.3.9. Briefly, McCoy cells (a mouse cell line) in cycloheximide EMEM with 10% fetal bovine serum (FBS) are used as hosts. Prior to chlamydial inoculation, the maintenance medium is aspirated without disruption of the cell layer and the cell layer is maintained on a cover slip in a standard vial. Each vial is then inoculated with 100-300 μ L inoculum and centrifuged at 3500 x g for one hour at 20°C. The fluid is then aspirated and 1 ml of EMEM is added. The vials are capped and incubated at 37°C for 48 hours. After 48 hours the medium is again aspirated, coverslips are rinsed twice with PBS and fixed with 300 μ L EtOH for 10 minutes. The EtOH is aspirated and the vials are allowed to dry; then one drop PBS plus 30 μ L Syva Microtrak monoclonal antibody to the major outer membrane protein of *Chlamydia* is added for staining. After 37°C incubation for 30 minutes, the cells are washed with distilled water and examined for inclusions which are easily recognizable as bright, apple-green-staining cytoplasmic vacuoles. They represent the equivalent of a colony of free-living bacteria on standard bacterial culture media.

In the assays conducted below, *C. trachomatis* serovar L2 (L2/434Bu) described by Kuo, C.C. et al. in Nongynococcal Urethritis and Related Infections (1977), Taylor-Robinson, D. et al. Ed. Am. Soc. Microbiol. Washington, D.C., pp. 322-326 was used. The seed is prepared from a sonicated culture in L929 mouse fibroblast cells, and partially purified by centrifugation. Since host protein is still present in the seed aliquots, each seed batch is

titered at the time of preparation with serial ten-fold dilutions to 2×10^{-9} . The seed containing 9.2×10^6 IFU/ml is thawed quickly at 37°C and diluted to 10^{-2} with sucrose/phosphate salts/glycine to produce IFU of about 200 after room temperature preincubation and to dilute background eukaryotic protein.

In the initial assays, the peptides to be tested were prepared as stock solutions in 0.01% glacial acetic acid. 100 μL of the diluted chlamydial seed was aliquoted into 1.5 ml eppendorf tubes and 200 μL of the antibiotic peptide was added per tube. Aliquots of the peptide stock (and controls) were incubated with the seed at room temperature for one hour, two hours and four hours. About 10 minutes before the end of each incubation period, maintenance media were aspirated from the McCoy vials in preparation for standard inoculation and culture. Culture was then performed in the presence and absence of the peptides; in some cases, the peptides were added to final concentration in the culture media in addition to the preculture incubation. The test was evaluated microscopically.

The results using 50 μg of protegrin per addition were dramatic. In control cultures, where no peptides were added, 222-460 inclusions were counted. In all protocols where protegrin was added either before the *Chlamydia* seed was added to the cells or both before and after, no inclusions were found. Similar results were obtained with 20 μg additions of tachyplesin. The defensins NP-1 and HNP-1 had lesser protective effects. In summary, the protegrins tested show antimicrobial against *Chlamydia*.

In the next series of experiments, various concentrations of protegrin (1 μg , 12.5 μg , 25 μg and 50 μg) were used in the two-hour preincubation. Concentrations as low as 12.5 μg lowered the number of inclusions to zero. Even at a concentration of 1

$\mu\text{g/ml}$, the number of inclusions was lowered dramatically from about 110 to about 30.

In the next set of experiments, the effect of the presence of serum was tested. The *Chlamydia* seed was preincubated for two hours with and without 10% FBS and also with or without protegrin at 25 μg . Protegrin was highly effective both with and without serum, whereas human defensin HNP-2, used as a control, was reasonably effective in the absence of serum but only marginally effective in its presence.

The experiments were repeated but adding 25 μg of protegrin one after the start of the chlamydial culture, i.e., after centrifugation and final medium mix and one hour into the beginning of the 48-hour culture period. Protegrin reduced the number of inclusions by approximately 57% from untreated controls although HNP-2 was completely ineffective. Finally, the protegrin (at 25 μg) was added to the chlamydial seed and the mix then immediately cultured. In this case, without preincubation and without the one-hour post-infection gap, protegrin was minimally effective without or without serum.

The effect of serum is particularly important since for a topical agent to be effective in combatting *Chlamydia* infection, it must act in the presence of serum.

In addition, there are several mouse-based models for *Chlamydia* infection which can be used to assess the efficacy of the protegrins. These include those described by Patton, D.L. et al. in Chlamydial Infections (1990) Bowie, W.R. et al. Eds. Cambridge University Press NY pp. 223-231; Swenson, C.E. et al. J. Infect. Dis. (1983) pp. 1101-1107, and Barron, A.L. et al. J. Infect. Dis. (1981) 143:63-66.

Neisseria gonorrhoeae

In more detail, the ability of the protegrins to inhibit *N. gonorrhoeae* was tested by a modification of the method of Miyasaki et al., Antimicrob Agent Chemother (1993) 37:2710-2715.

5 Nonpiliated transparent variants of strains FA 19 and F 62 were propagated on GCB agar plates containing glucose and iron supplements overnight at 37°C under 3.8% V/V CO₂. These strains were chosen for their adaptability to the assay.

10 The overnight growth is removed from the agar plate and suspended in GCB broth containing supplements and sodium bicarbonate and grown with shaking at 37°C to mid log phase. The culture is diluted 1:100 in GCB broth to give about 10⁶ CFU/ml and
15 serial dilutions were plated onto GCB agar.

The peptides are dissolved in 0.01% v/v acetic acid to give a 1 mg/ml stock solution and serially diluted. Ten µl of each dilution is added to a sterile polystyrene tube containing 90 µl of diluted
20 bacteria and the tubes are shaken at 37°C for 45 minutes. The contents are serially diluted 1:10 and plated on to GCB agar plates which are incubated in a CO₂ incubator. CFU are counted after 24 hours and the log bactericidal activity calculated.

25 Native PG-1, synthetic PG-1, synthetic PG-3 amide and synthetic PG-3 without amidation all gave over a 5 log reduction in CFU per ml in this assay. Native PG-2 (containing 16 amino acids) gave a 2.6 fold reduction.

30 In addition enantioPG-1, the unidisulfide PG-1 (C₆-C₁₅), and unisulfide PG-1 (C₈-C₁₃) gave over a 5-fold log reduction in CFU/ml in this assay.

Treponema pallidum

35 Bacteriocidal activity against this organism, which is the etiologic agent of syphilis, was also tested. Peptides were evaluated at a series

of concentrations of 1.758 μg to 56.25 μg in 90 μl of unheated normal rabbit serum. The serum served as a nutrient for the spirochetes to allow their survival during incubation as well as providing a source of complement. Ten μl of a suspension of *T. pallidum* containing about $5 \times 10^7/\mu\text{l}$ organisms was added to each tube and the mixtures with the appropriate peptides were incubated at 34°C under 95% N_2 and 5% CO_2 . At time zero, just prior to incubation, 4 hours and 16 hours, 25 randomly selected organisms were examined for the presence or absence of motility. The 50% immobilizing end point (IE_{50}) was calculated to indicate the concentration needed to immobilize 50% of the spirochetes. In the presence of PG-1, the IE_{50} at 0 and 4 hours was 2.717 μg and < 1.758 μg , respectively. Tachyplesin IE_{50} 's were 5.231 μg and 2.539 μg for 0 and 4 hours. This was in contrast to HNP and NP preparations which showed little immobilizing ability.

Herpes Simplex Virus

Using viral stocks prepared in VERO cells, grown in minimal essential medium (MEM) with 2% fetal calf serum, the effect of various peptides on HSV 1 MacIntyre strain, a pool of ten clinical HSV 1 isolates, HSV-2G, and a pool of ten clinical HSV 2 isolates, all sensitive to 3 μM acyclovir were tested. Two fibroblast cell lines, human W138 and equine CCL57, were used as targets and tests were done by direct viral neutralization and delayed peptide addition.

In the direct neutralization format, the virus was preincubated with the peptides for 90 min before it was added to the tissue culture monolayers. In the delayed peptide addition format, the virus was added and allowed 50 min to adsorb to the target cells, then the monolayers were washed and peptides were added for 90 min. Finally, the monolayer was

washed to remove the peptide and the cells were fed with peptide-free MEM and cultured until the untreated infected monolayers exhibited 4+ cytopathic effect (CPE) (about 60 hours).

5 Antiviral activity was seen in both formats, but was more pronounced with the delayed peptide addition mode. In experiments performed with W138 and CCL57 cells in the direct neutralization format, PG-1 completely prevented HSV-2G from causing CPE at
10 concentrations of 50 μ g/ml and 25 μ g/ml, but these concentrations afforded no protection against HSV-1, which produced 4+ CPE.

 In the delayed peptide addition format, PG-1 completely prevented CPE by HSV-2G at 35 μ g/ml and 50
15 μ g/ml and it also fully protected against the clinical HSV-2 pool at both concentrations.

 Thus, PG-1 protected human and animal cells from infection by laboratory and clinical strains of HSV-2, even when the peptides were added as late as 60
20 min after the virus had been introduced into the cell culture.

Trichomonas vaginalis

Trichomonas vaginalis strain C1 (ATCC 30001) was grown as described by Gorrell, T.E. et al, 25
Carlsberg Res Comm (1984) 49:259-268. In experiments performed in RPMI + 1% heat-activated fetal calf serum, within a few minutes after exposure to 50 μ g/ml PG-1, *T. vaginalis* (heretofore vigorously motile) became stationary. Soon thereafter, the organisms
30 became permeable to trypan blue, and, over the ensuing 15-30 minutes, lysed. As expected, such organisms failed to grow when introduced into their customary growth medium (Diamond's medium). Organisms exposed to 25 μ g/ml of PG-3 retained their motility.

35 Initial studies with two highly metronidazole-resistant clinical isolates of *T.*

vaginallis, strains MR and TV showed both were susceptible to PG-1, including the C₈-C₁₃ and C₆-C₁₅ disulfides and enantioPG-1 at concentrations of 100 and 50 µg/ml.

5

Example 10Antiretroviral Activity

Both synthetic and native PG-1 and native PG-2 were tested for antiviral activity against strains of HIV using the method described in Miles, S.A. et al., Blood (1991) 78:3200-3208. Briefly, the mononuclear cell fraction is recovered from normal donor leukopacs from the American Red Cross using a Ficoll-hypaque density gradient. The mononuclear cells are resuspended at 1×10^6 cells per ml in RPMI 1640 medium with 20% fetal bovine serum, 1% penn/strep with fungizone and 0.5% PHA and incubated 24 hours at 37°C in 5% CO₂. The cells are centrifuged, washed and then expanded for 24 hours in growth medium.

Non-laboratory adapted, cloned HIV_{JR-CSF} and HIV_{JR-FL} were electroporated into the human peripheral blood mononuclear cells prepared as described above. Titers were determined and in general, multiplicities of infection (MOI) of about 4,000 infectious units per cell are used (which corresponds to 25-40 picograms per ml HIV p24 antigen in the supernatant).

In the assay, the HIV stocks prepared as above were diluted to the correct MOI and the PBM are added to 24 well plates at a concentration of 2×10^6 per ml. One µl total volume is added to each well. The peptide to be tested is added in growth medium to achieve the final desired concentration. Then the appropriate number of MOI are added. To assay viral growth, 200 µl of supernatant is removed on days 3 and 7 and the concentration of p24 antigen is determined using a commercial assay (Coulter Immunology, Hialeah, Florida). Controls include duplicate wells

containing cells alone, cells plus peptide at 5 $\mu\text{g/ml}$ cells with virus but not peptide and cells with virus in the presence of AZT at $10^{-5}\text{ M} - 10^{-8}\text{ M}$.


Using this assay, it was demonstrated that both natural and synthetic PG-1 completely inhibit HIV infection at concentrations between 1-5 $\mu\text{g/ml}$; IC_{50} was < 5 $\mu\text{g/ml}$. The time of addition of peptide was then varied. Cells pretreated for 2 hours prior to addition of virus, at the time of addition of virus, or 2 hours after infection showed antiviral activity for the peptide. However, if PG-1 was added 24 hours after infection, there was no antiviral activity.

Further, PG-2 shows similar activity but at a level approximately 5-fold less. Alternative antibiotics such as human defensins and rabbit defensins lacked potent activity in this assay. The results were similar for both $\text{HIV}_{\text{JR-CSF}}$ and $\text{HIV}_{\text{JR-FL}}$ which are non-laboratory adapted isolates (Koyanagi, Y.S. et al, Science (1987) 236:819-822).

The protegrins show similar activity with respect to other retroviruses.

Claims

1. A compound of the formula



and the N-terminal acylated and/or
C-terminal amidated or esterified forms thereof, which
is either in the optionally -SH stabilized linear or
in a cystine-bridged form

wherein each of A_1 and A_9 is independently a
basic amino acid;

each of A_2 and A_3 is independently a small
amino acid;

each of A_5 , A_7 , A_{12} , A_{14} and A_{16} is
independently a hydrophobic amino acid;

each of A_4 and A_{10} is independently a basic or
a small amino acid;

A_{11} is a basic or a hydrophobic amino acid;

A_{17} is not present or, if present, is a small
amino acid;

A_{18} is not present or, if present, is a basic
amino acid, or a

modified form of formula (1) and the
N-terminal acylated and/or C-terminal amidated or
esterified forms thereof wherein each of 1-4 cysteines
is independently replaced by a hydrophobic amino acid
or a small amino acid;

with the proviso that if said compound is of
the formula

RGGRLCYCRRRFCVGVGR,

RGGRLCYCRRRFCICV,

RGGGLCYCRRRFCVGVGR, or

RGGRLCYCRGWICFCVGR

in the amidated and di-cystine-bridged form, said
compound is purified and isolated.

2. The compound of claim 1 which contains two cystine bridges;

and/or wherein the C-terminal carboxyl is of the formula selected from the group consisting of COOH or the salts thereof; COOR, CONH₂, CONHR, and CONR₂, wherein each R is independently hydrocarbyl(1-6C);

and/or wherein the amino group at the N-terminus is of the formula NH₂ or NHCOR wherein R is hydrocarbyl(1-6C);

and/or wherein each of A₁ and A₉ is independently selected from the group consisting of R, K and Har;

and/or wherein each of A₂ and A₃ is selected independently from the group consisting of G, A, S and T;

and/or wherein A₄ is R or G; and/or wherein each of A₅, A₁₄ and A₁₆ is independently selected from the group consisting of I, V, NLe, L and F;

and/or wherein each of A₇ and A₁₂ is independently selected from the group consisting of I, V, L, W, Y and F;

and/or wherein each of A₁₀ and A₁₁ is independently R, G or W.

3. The compound of claim 1 which contains one cystine bridge;

and/or wherein the C-terminal carboxyl is of the formula selected from the group consisting of COOH or the salts thereof; COOR, CONH₂, CONHR, and CONR₂, wherein each R is independently hydrocarbyl(1-6C);

and/or wherein the amino group at the N-terminus is of the formula NH₂ or NHCOR wherein R is hydrocarbyl(1-6C);

and/or wherein each of A₁ and A₉ is independently selected from the group consisting of R, K and Har;

and/or wherein each of A_2 and A_3 is selected independently from the group consisting of G, A, S and T;

and/or wherein A_4 is R or G;

5 and/or wherein each of A_5 , A_{14} and A_{16} is independently selected from the group consisting of I, V, NLe, L and F;

and/or wherein each of A_7 and A_{12} is independently selected from the group consisting of I, V, L, W, Y and F;

10 and/or wherein each of A_{10} and A_{11} is independently R, G or W.

4. The compound of claim 1 which is in the linear form;

15 and/or wherein the C-terminal carboxyl is of the formula selected from the group consisting of COOH or the salts thereof; COOR, CONH₂, CONHR, and CONR₂ wherein each R is independently hydrocarbyl(1-6C);

20 and/or wherein the amino group at the N-terminus is of the formula NH₂ or NHCOR wherein R is hydrocarbyl(1-6C);

and/or wherein each of A_1 and A_9 is independently selected from the group consisting of R, K and Har;

25 and/or wherein each of A_2 and A_3 is selected independently from the group consisting of G, A, S and T;

and/or wherein A_4 is R or G;

and/or wherein each of A_5 , A_{14} and A_{16} is independently selected from the group consisting of I, V, NLe, L and F;

30 and/or wherein each of A_7 and A_{12} is independently selected from the group consisting of I, V, L, W, Y and F;

and/or wherein each of A_{10} and A_{11} is independently R, G or W.

5. The compound of claim 1 which is in the modified form;

and/or wherein the C-terminal carboxyl is of the formula selected from the group consisting of COOH or the salts thereof; COOR, CONH₂, CONHR, and CONR₂,
5 wherein each R is independently hydrocarbyl(1-6C);

and/or wherein the amino group at the N-terminus is of the formula NH₂ or NHCOR wherein R is hydrocarbyl(1-6C);

10 and/or wherein each of A₁ and A₉ is independently selected from the group consisting of R, K and Har;

and/or wherein each of A₂ and A₃ is selected independently from the group consisting of G, A, S and
15 T; and/or wherein A₄ is R or G;

and/or wherein each of A₅, A₁₄ and A₁₆ is independently selected from the group consisting of I, V, NLe, L and F;

and/or wherein each of A₇ and A₁₂ is independently selected from the group consisting of I,
20 V, L, W, Y and F;

and/or wherein each of A₁₀ and A₁₁ is independently R, G or W.

25 6. The compound of claim 2 wherein said cystine bridges link C₆-C₁₅ and C₈-C₁₃.

7. The compound of claim 3 wherein said cystine bridges link C₆-C₁₅ or C₈-C₁₃.

8. The compound of claim 5 wherein each of said 1-4 cysteines is independently replaced by G, A,
30 S, T, I, V, or L.

9. The compound of claim 1 which is selected from the group consisting of

PG-1: RGGRLCYRRRFCVVCVGR

PG-2: RGGRLCYCRRRFCICV

PG-3: RGGGLCYCRRRFCVCVGR

PG-4: RGGRLCYCRGWICFCVGR

5 and the amidated forms thereof either in
linear or cystine-bridged form.

10. The compound of any of claims 1-9
wherein all amino acids are in the D-configuration.

11. A purified and isolated compound of the
formula:

10 $A_1-A_2-A_3-A_4-A_5-C_6-A_7-C_8-A_9-A_{10}-A_{11}-A_{12}-C_{13}-A_{14}-C_{15}-A_{16}-(A_{17}-A_{18})$
(1a)

and the N-terminal acylated, C-terminal
amidated or esterified forms thereof in either the
linearized or the cystine-bridged form

15 wherein each A_n is independently an amino
acid at the designated position and wherein said
cystine-bridged compound is isolatable from the
leukocytes of an animal subject by a process which
comprises subjecting the ultrafiltrate of a lysate of
20 said leukocytes to chromatographic separation
techniques to obtain a fraction containing compounds
of Formula (1a) and recovering said compounds of
Formula (1a).

25 12. A peptide in purified and isolated form
having antimicrobial and/or antiviral activity which
is encoded by a DNA which hybridizes under stringent
conditions to the DNA of porcine leukocytes which
encodes PG-1, PG-2, PG-3 or PG-4.

30 13. A purified and isolated DNA which
hybridizes under stringent conditions to the DNA of
porcine leukocytes which encodes PG-1, PG-2, PG-3 or
PG-4.

5 14. A recombinant expression system for production of a peptide having the amino acid sequence of the compound of any of claims 1-9 which expression system comprises a nucleotide sequence encoding said peptide operably linked to control sequences for effecting expression.

15. A recombinant host cell modified to contain the expression system of claim 14.

10 16. A method to produce an antimicrobial or antiviral peptide or intermediate peptide therefor which method comprises culturing the modified host cells of claim 15 under conditions wherein said peptide is produced; and recovering the peptide from the culture.

15 17. The method of claim 16 which further comprises effecting cystine linkages of said peptide and/or modifying the N-terminus and/or C-terminus of said peptide.

20 18. A pharmaceutical composition for antimicrobial or antiviral use which comprises the compound of any of claims 1-12 in admixture with at least one pharmaceutically acceptable excipient.

25 19. A composition for application to plants or plant environments for conferring resistance to microbial or viral infection in plants which comprises the compound of claims 1-12 in admixture with at least one environmentally acceptable diluent.

30 20. A method to prevent the growth of a virus or microbe which method comprises contacting a composition which supports the growth of said virus or

microbe with an amount of the compound of any of claims 1-12 effective to prevent said growth.

21. The method of claim 20 wherein said composition is an eye care product.


5 22. The compound of any of claims 1-12 for use in treating a sexually transmitted disease.

10 23. A method to inactivate the endotoxin of gram-negative bacteria, which method comprises contacting said endotoxin with an amount of the compound of any of claims 1-12 effective to inactivate said endotoxin.


24. The compound of any of claims 1-12 for use in treating septic shock.

15 25. Antibodies specifically reactive with the compound of any of claims 1-12.

1 / 14



F I G. 1



F I G. 2

2 / 14




FIG. 3




FIG. 4a




FIG. 4b




FIG. 4c

4 / 14




FIG. 4d

5/14




FIG. 4e

6/14




FIG. 5a-1




FIG. 5a-2




FIG. 5b-1




FIG. 5b-2




FIG. 5c-1




FIG. 5c-2




FIG. 6a




FIG. 6b




FIG. 6c




FIG. 6d

10/14




FIG. 6e




FIG. 6f

11/14

10	20	30	40	50	
ATGGAGACCCAGAGAGCCAGCCTGTGCCTGGGGCGCTGGTCACTGTGGCTTCTGCTGCTG	60				
METGluThrGlnArgAlaSerLeuCysLeuGlyArgTrpSerLeuTrpLeuLeuLeuLeu	20				
GCACTCGTGGTGGCCTCGGCCAGCGCCAGGCCCTCAGCTACAGGGAGGCCGTGCTTCGT	120				
AlaLeuValValProSerAlaSerAlaGlnAlaLeuSerTyrArgGluAlaValLeuArg	40				
GCTGTGGATCGCCTCAACGAGCAGTCCTCGGAAGCTAATCTCTACCGCCTCCTGGAGCTG	180				
AlaValAspArgLeuAsnGluGlnSerSerGluAlaAsnLeuTyrArgLeuLeuGluLeu	60				
GACCAGCCGCCAAGGCCGACGAGGACCCGGGCACCCCGAAACCTGTGAGCTTCACGGTG	240				
AspGlnProProLysAlaAspGluAspProGlyThrProLysProValSerPheThrVal	80				
AAGGAGACTGTGTGTCCCAGGCCGACCCGGCAGCCCCGGAGCTGTGTGACTTCAAGGAG	300				
LysGluThrValCysProArgProThrArgGlnProProGluLeuCysAspPheLysGlu	100				
AACGGGCGGGTGAAACAGTGTGTGGGGACAGTCACCCTGGATCAGATCAAGGACCCGCTC	360				
AsnGlyArgValLysGlnCysValGlyThrValThrLeuAspGlnIleLysAspProLeu	120				
GACATCACCTGCAATGAGGTTCAAGGTGTCAGGGGAGGTGCGCTGTGCTATTGTAGGCGT	420				
AspIleThrCysAsnGluValGlnGlyValArgGlyGlyArgLeuCysTyrCysArgArg	140				
			Gly ³	Gly ⁴	
T ⁴ A ⁴ A ² T ⁴ T ²					
AGGTTCTGCGTCTGTGTGCGGACGAGGATGACGGTTGCGACGGCAGGCTTTCCTCCCCCA	480				
ArgPheCysValCysValGlyArgGly---	149				
Trp ⁴ Ile ⁴ Phe ⁴ Ile ² ---2					
ATTTTCCCGGGGCCAGGTTTCCGTCCCCCAATTTTCCGCTCCACCTTTCGGCCCCGCA	540				
CCATTGCGTCCACCAAGGTTCCCTGGTAGACGGTGAAGGATTTGCAGGCAACTCACCCAG	600				
			A ² G ²		
AAGGCCTTTCGGTACATTAAATCCCAGCAAGGAGACCTAAGCATCTGCTTTGCCAGGC	660				
CCGCATCTGTCAAATAAATTCTTGTGAAACC	691				

FIG. 7

12 / 14

PG-1	² RGG	⁴ R	^{6 8} LCYCR	^{10 12} RRF	C	¹⁴ V	^{16 18} CVGR	(NH ₂)
PG-2	RGG	R	LCYCR	RRF	C	I	CV	(NH ₂)
PG-3	RGG	G	LCYCR	RRF	C	V	CVGR	(NH ₂)
PG-4	RGG	R	LCYCR	GWI	C	F	CVGR	(G)

FIG. 8

13/14




FIG. 9a






FIG. 9b

14 / 14



F I G. 9c



F I G. 9d

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/08305

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/69.1, 240.1, 320.1; 514/13; 530/326, 387.1; 536/23.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, DIALOG, SWISSPROT, UEMBL, PIR, GENBANK, search terms: sequences, peptide

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	The Journal of Biological Chemistry, Volume 260, Number 8, issued 25 April 1985, Selsted et al., "Primary structures of six antimicrobial peptides of rabbit peritoneal neutrophils", pages 4579-4584, see whole publication. especially page 4581.	1-17
A,P	Federation of European Biochemical Societies, Volume 327, Number 2, issued 26 July 1993, Kokryakov et al., "Protegrins: leukocyte antimicrobial peptides that combine features of corticostatic defensins and tachyplesins", pages 231-236, see whole publication.	1-17

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

12 OCTOBER 1994

Date of mailing of the international search report

02 NOV 1994

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

KEITH FURMAN, PH.D.

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/08305

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A,P	Federation of European Biochemical Societies, Volume 330, Number 3, issued September 1993, Mirgorodskaya et al., "Primary structure of three cationic peptides from porcine neutrophils: sequence determination by the combined usage of electrospray ionization mass spectrometry and Edman degradation", pages 339-342, see whole publication.	1-17

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/08305

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claims Nos.: 18-25
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US94/08305

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (5):

C07K 7/00, 7/08, 7/64, 15/08, 15/28; C12N 15/03, 15/04, 15/05, 15/06, 15/12; A61K 37/02

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

435/69.1, 240.1, 320.1; 514/13; 530/326, 387.1; 536/23.5